Conference Coverage
Conference Coverage
Few with inflammatory breast cancer get guideline-based care
A retrospective study of patients with inflammatory breast cancer shows that the majority of patients don’t receive guideline-based care.
Conference Coverage
SCD mortality rates improved for Black patients in 2010s
The average age at death rose 4 years during that decade, but the transition from pediatric to adult care remains a major danger zone.
Conference Coverage
MRD status predicts transplant benefit in NPM1-mutated AML
Certain patients with NPM1-mutated acute myeloid leukemia and measurable residual disease were shown to benefit from transplantation.
Conference Coverage
Sickle Cell: Good Outcomes for Haploidentical Transplants
Overall 2-year survival was 95% in a small, “robust” phase-2 trial of children and adults with sickle cell disease.
Conference Coverage
Measurable residual disease–guided therapy promising for CLL
Phase-3 analysis shows that a drug combo for chronic lymphocytic leukemia yielded better outcomes than chemoimmunotherapy.
Conference Coverage
Mantle Cell Lymphoma: Drug Combo Improves PFS
Interim analysis of the new study, however, finds no statistically significant boost in overall survival.
Conference Coverage
‘Baby TAM’ effective, tolerable for breast cancer prevention
A new study shows that a lower dose of tamoxifen leads to better adherence, and another shows similar efficacy at reducing breast density.
Conference Coverage
Living in a Food Swamp Tied to High Breast Cancer Mortality
New research shows higher postmenopausal breast cancer mortality in communities with easier access to unhealthy fast food.
Conference Coverage
Oncotype Score Helps Avoid Unnecessary Radiation in DCIS
Using a gene test to guide radiation decisions may reduce overtreatment in ductal carcinoma in situ.
Conference Coverage
Distinct toxicity profiles for anti-BCMA myeloma therapies
New FDA data analysis shows CAR T-cell and other anti-BCMA treatments for multiple myeloma are linked to considerable risks for side effects.
Conference Coverage
Myeloma: Isatuximab Four-Drug Regimen Boosts MRD Negativity
Quadruplet regimen with anti-CD38 drug isatuximab improved MRD negativity vs. the standard triplet regimen in newly diagnosed myeloma patients.